Project Grant R44HL176351
Award Date
9/25/24
Completion Date
6/30/26
Dollars Obligated
$1.2M
Federal Agency
National Heart Lung and Blood Institute
Awardee
Sanaheal Inc. (HQUQS5MGF156)
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Cambridge, MA 02139, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $295,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Hematherix LLC, a woman-owned small business in California. The award supports the development of SuperFVa, an engineered variant of activated coagulation cofactor Factor V, as a targeted therapy to prevent and correct acute traumatic coagulopathy (ATC). ATC is characterized by diminished levels of key clotting factors, leading to...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,095,816 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The DNA Medicine Institute, Inc. to develop a 5-minute point-of-care test for measuring anti-Factor Xa activity and hemoglobin levels. This rapid diagnostic tool is intended to guide emergency management of bleeding and strokes in patients on anti-Xa direct oral anticoagulants. The grant aims to leverage the company's existing technology, including a...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $234,000 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Colorado-Denver to engineer and test "hemostatic red blood cells" (T-RBCs) for the treatment of acute non-compressible hemorrhage. The key objectives are to: 1) engineer T-RBCs that bind to collagen and fibrin to enhance clot formation and stability, 2) perform in vitro testing of the T-RBCs' hemostatic properties, and 3)...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $944,676 to Haima Therapeutics LLC, a woman-owned small business, to develop a novel platelet-inspired nanotechnology to restore hemostasis in patients on antiplatelet agents. The goal is to create a synthetic, donor-independent therapeutic that can effectively restore hemostatic function in traumatic brain injury (TBI) patients taking P2Y12 inhibitors, which...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $295,963 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to New Health Sciences, Inc. (Hemanext Inc.) to evaluate the hemostatic function of platelets stored under hypoxic conditions for whole blood (WB) transfusion. The project aims to develop an improved WB storage platform that maintains an oxygen-managed environment to provide higher quality red blood cells for oxygen delivery and shock reversal, while...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $306,656 to Bioparin, LLC to develop biotechnological approaches for expeditious synthesis of heparin-like anticoagulants using engineered microbial cellular factories. The award aims to address challenges in securing reliable sources of animal-derived heparin, a critical medicine for treating thrombosis and other clotting disorders,...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,250,837 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute, to develop a gene editing approach using lipid nanoparticles (LNPs) and CRISPR/Cas9 tools to permanently correct the mutated Factor VIII (FVIII) gene and restore FVIII expression for the treatment of hemophilia A. The project aims to enhance LSEC-targeting of LNPs and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $306,102 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Peca Labs Inc. on August 1, 2025. The grant funds the development and feasibility testing of a novel, fully-polymeric, biomimetic prosthetic mitral valve constructed from clinically-proven materials. The goal is to improve durability, performance, and overall outcomes compared to current biologic and mechanical valve options. Specific aims include...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $1,435,366 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Oregon Health & Science University. The grant, titled "Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study," will conduct a multicenter clinical trial to evaluate the effectiveness of progestin treatments in managing heavy menstrual bleeding and improving quality of life for adolescents and young adults...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $420,600 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the University of Colorado-Denver. The grant's objective is to design elastic hydrogel microparticles as a platform to measure key elements of platelet function, including adhesion, activation, aggregation, and contraction. This innovative "lab-on-a-particle" approach aims to improve the reliability and reproducibility of platelet function...